Logo

Thermo Fisher Scientific Completes Sale of Genevac

Apr 04, 2007
NEW YORK (GenomeWeb News) — Thermo Fisher Scientific today said it has completed the sale of its Genevac business to Riverlake Equity Partners.
 
Thermo said Genevac brought in around $17 million in annual sales.
 
As GenomeWeb News reported last October, the Federal Trade Commission and the European Commission required that Fisher Scientific divest the Ipswich, UK-based company before it can merge with Thermo Electron.
 
The FTC and the EC required Thermo to sell the business by April 9.

Breaking News
The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.